

Financial Tear Sheet

Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

Primary IR Contact

Stern Investor Relations, Inc.

Sarah McCabe

Phone: 212-362-1200

E-mail:

sarah@sternir.com

Stock Performance

IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$8.70**

Change (%) ▼ 0.2 (2.25%)

Volume 737,022

52 Week High \$9.18

52 Week Low \$4.45

Market Cap \$631,904,638

Rolling EPS -1.31

PE Ratio 0

Shares Outstanding 72,632,717

Data as of December 13, 2017 4:00 p.m. ET



Recent Headlines

December 13, 2017

[Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017](#)

December 13, 2017

[Iovance Biotherapeutics Expands Pipeline of TIL Therapies into Lung Cancer](#)

December 7, 2017

[Iovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017](#)

SEC Filings

Filing Date	Form
December 13, 2017	8-K
December 1, 2017	424B3
November 13, 2017	8-K
November 2, 2017	10-Q

Data provided by Nasdaq. Minimum 15 minutes delayed.

Upcoming Events

Date	Title
December 13, 2017 9:00 a.m. ET	Analyst and Investor Day

Corporate Governance

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.